MRNY climbed roughly 157% over the past 30 days, from about $14.36 to $36.97, almost entirely because of a single-session breakout in Moderna ( MRNA ). The catalyst was positive Phase 3 results for Moderna and Merck's personalized mRNA cancer vaccine in high-risk melanoma, a first for the class.

CRCG is a single-stock leveraged exchange-traded fund (ETF) that seeks to deliver twice (2x) the daily return of Circle Internet Group (CRCL), the issuer of the USD Coin (USDC) stablecoin. The fund has gained roughly 105% over the trailing 30 days, recovering from its late-July and early-August lows.

BMNU surged roughly +81% over the trailing 30 days, driven by a sharp late-summer rally in digital assets that lifted its sole underlying exposure. The fund seeks 200% daily (2x) leveraged exposure to Bitmine Immersion Technologies (NYSE: BMNR), amplifying both the stock's gains and its losses.

ETHT, a 2x daily leveraged Ether (Ethereum) fund, rose roughly 58% over the last 30 days, tracking one of Ether's sharpest rallies of the year. Over the trailing quarter, ETHT gained about 66% , though the path was exceptionally volatile, with a 52-week low near $7 in late June preceding the rebound.

SNXX climbed roughly 47% over the last 30 days, rising from about $9.34 to $13.71 per share. Over the trailing three months, however, the fund is down approximately 54%, reflecting a sharp mid-2026 drawdown followed by only a partial rebound.

Housing cycle exposure: Quanex's trajectory is closely tied to North American and European new-build and repair-and-remodel activity, making interest-rate policy and mortgage affordability the dominant macro levers. Tyman integration and synergies: The 2024 acquisition of Tyman remains a central value driver, with management targeting roughly $30 million in annual cost synergies and continued debt reduction.

Micron closed up +6.10% at $1,016.59 in regular Friday trading, adding +$58.43 versus the prior close of $958.16 and breaking above the $1,000 mark. The move was driven by the AI-memory supercycle: Susquehanna and TechInsights flagged DRAM contract prices set to jump 50%–200% and NAND about +60% this quarter.

Micron Technology shares rose roughly 15.8% over the trailing 30 days, climbing from about $877.57 on Aug. 7 to a close of $1,016.59 on Sept. 4, 2026. The advance has been fueled by an AI-driven memory boom: tight DRAM, NAND, and high-bandwidth memory (HBM) supply combined with strong demand from data-center and AI infrastructure buildouts.

BE is the stock ticker for Bloom Energy Corporation, a clean-energy technology company headquartered in San Jose, California. The company designs, manufactures, sells, and installs solid oxide fuel cell (SOFC) systems that generate electricity on-site without combustion.

Selected price target: $1.00, roughly 49% above the latest price near $0.67, representing both a round-number milestone and Nasdaq's minimum bid price threshold. Strongest bullish factors: FDA approval of LYTENAVA for wet age-related macular degeneration (AMD), a planned U.S. commercial launch, and a "Buy"-leaning analyst consensus with targets well above $1.

CRDO shares fell roughly 24% over the past 30 days, sliding from about $224.63 to $170.57, driven by a sharp post-earnings selloff in early September 2026. The decline followed a "beat-and-raise" fiscal Q1 2027 report in which revenue rose about 115% year over year to $479 million and adjusted EPS of $1.20 topped estimates.

CIEN shares declined about 22% over the last 30 days, falling from roughly $412 to $321, and are down about 34% over the trailing three months. The drop occurred despite strong fundamentals: fiscal third-quarter 2026 revenue rose 37% year over year to $1.67 billion, and adjusted EPS climbed 215% to $2.11.

AppLovin (APP) fell roughly 23% over the last 30 days, from a closing price near $417.80 to about $320.56, driven by a disappointing second-quarter earnings report. The August 5 results marked AppLovin's first revenue miss in four quarters, with revenue of $1.92 billion coming in below the roughly $1.94 billion consensus estimate.

Investors are actively debating whether SMCI can climb to $100 , a level more than double its recent price near $40. The bull case rests on explosive AI-server demand, a record $60 billion-plus in new orders, and a sharp rebound in gross margins.

Selected price target: $200 per share — roughly the consensus Wall Street analyst price target and a round-number milestone just below the stock's 52-week high. Current position: Shares trade near $126, well below the $212.12 52-week high reached after the BRINSUPRI approval, meaning a move to $200 implies roughly 58% upside.

The widely discussed $140 price target , reiterated by Bernstein, implies roughly 37% upside from Circle's recent trading level near $102. The strongest bullish case rests on USDC (USD Coin) stablecoin growth, an expanding fee-based product suite, and Circle's push into tokenized finance and AI-driven payments.

Medline shares have been roughly flat over the trailing 30 days, holding near the $36–37 range after a volatile summer that saw the stock slide from its early-August highs. Second-quarter 2026 revenue rose 11.6% year over year to $7.7 billion, while net income fell 58.3% amid tariff headwinds and higher operating costs.

Modine Manufacturing (MOD) shares were roughly flat over the trailing 30 days, moving only a fraction of a percent between early August and early September. Despite the near-term stabilization, the stock has declined approximately 20% from its early-July levels, reflecting a volatile quarter.

NCLH shares fell roughly 19% over the last 30 days, from about $19.25 to near $15.57, as investors digested weaker guidance and multiple analyst downgrades. Second-quarter adjusted EPS of $0.48 beat estimates, but full-year 2026 guidance was cut and third-quarter net yield is projected to decline 8.9%.

DKS shares fell roughly 30.5% over the past 30 days, with most of the decline coming in a record single-session drop of about 31% on Aug. 25, 2026. The selloff followed a second-quarter fiscal 2026 earnings miss and a steep cut to full-year guidance tied to weakness in the acquired Foot Locker business.